Literature DB >> 25805446

Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.

Xuan Zhang1, Yannan Kong2, Jie Zhang3, Mingbo Su4, Yubo Zhou4, Yi Zang4, Jia Li4, Yi Chen3, Yanfen Fang5, Xiongwen Zhang2, Wei Lu6.   

Abstract

A new class of colchicine derivatives were designed and synthesized as tubulin-HDAC dual inhibitors. Biological evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymerization analysis, in vitro cell cycle analysis in HCT-116 cells and cytotoxicity against different cancer cell lines. Hybrid 6d behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine. Compound 11a exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Colchicine; Dual inhibitor; HDAC; Hybrid; Tubulin

Mesh:

Substances:

Year:  2015        PMID: 25805446     DOI: 10.1016/j.ejmech.2015.03.035

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  11 in total

1.  Phenethyisoquinoline alkaloids from the leaves of Androcymbium palaestinum.

Authors:  Tamam El-Elimat; Maram B Alhawarri; José Rivera-Chávez; Joanna E Burdette; Austin Czarnecki; Mohammad Al-Gharaibeh; Ahmed H Al Sharie; Ahmed Alhusban; Feras Q Alali; Nicholas H Oberlies
Journal:  Fitoterapia       Date:  2020-08-21       Impact factor: 2.882

Review 2.  Histone Deacetylase Inhibitors: A Prospect in Drug Discovery.

Authors:  Rakesh Yadav; Pooja Mishra; Divya Yadav
Journal:  Turk J Pharm Sci       Date:  2018-12-31

Review 3.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 4.  Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.

Authors:  Alexandria M Chan; Steven Fletcher
Journal:  RSC Med Chem       Date:  2020-12-11

5.  Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents.

Authors:  Ahmed M Shawky; Nashwa A Ibrahim; Ashraf N Abdalla; Mohammed A S Abourehab; Ahmed M Gouda
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 6.  Epigenetic polypharmacology: from combination therapy to multitargeted drugs.

Authors:  Angel R de Lera; A Ganesan
Journal:  Clin Epigenetics       Date:  2016-10-12       Impact factor: 6.551

7.  Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives.

Authors:  Urszula Majcher; Greta Klejborowska; Mahshad Moshari; Ewa Maj; Joanna Wietrzyk; Franz Bartl; Jack A Tuszynski; Adam Huczyński
Journal:  Cells       Date:  2018-11-01       Impact factor: 6.600

8.  Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine.

Authors:  Dominika Czerwonka; Szymon Sobczak; Ewa Maj; Joanna Wietrzyk; Andrzej Katrusiak; Adam Huczyński
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

Review 9.  Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

Authors:  Joshua P Smalley; Shaun M Cowley; James T Hodgkinson
Journal:  Molecules       Date:  2020-09-24       Impact factor: 4.411

Review 10.  Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.

Authors:  Dusan Ruzic; Nemanja Djoković; Tatjana Srdić-Rajić; Cesar Echeverria; Katarina Nikolic; Juan F Santibanez
Journal:  Pharmaceutics       Date:  2022-01-16       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.